Pharma Accounting UK

    Pharmaceutical businesses combine commercial finance with tightly controlled products, long development cycles and demanding evidence requirements. A manufacturer, research company and medicines wholesaler need different accounting structures even when they sit in the same group. PRS can help build dependable ledgers, project-cost records and financial reporting that distinguish scientific development, licensed supply and routine trading. Financial support should complement, not replace, the work of qualified regulatory, scientific and legal specialists. A successful month-end must explain the movement of cash and stock as well as the status of development expenditure.

    Key UK challenges

    Use batch and expiry information in stock valuation

    Connect the inventory ledger to batch numbers, expiry dates, quarantine status and released quantities. Stock awaiting a quality decision should not disappear from financial records, but its recoverable value may differ from freely saleable inventory. Assess short-dated medicines using realistic demand, contractual returns and disposal costs. Separate physical destruction, supplier credits and accounting write-downs so the same loss is not counted twice. Review inventory held by contract manufacturers or logistics providers and establish ownership rather than assuming that goods outside the company's premises belong to someone else.

    Tax & compliance

    Keep regulatory obligations visible in budgets

    MHRA guidance distinguishes manufacturing licences and wholesale distribution authorisations, with good manufacturing practice and good distribution practice requirements as appropriate. GDP covers obtaining medicines from the licensed supply chain and storing, transporting and handling them under suitable conditions. Budgets should reflect responsible personnel, validation, monitoring, inspection preparation and recall capability. Financial reconciliation does not certify regulatory compliance, and PRS should not be described as issuing GMP or GDP certification. Keep licence fees and routine compliance expenditure distinguishable from development projects when assessing accounting and tax treatment.

    Financial management

    Do not apply one VAT rate to every medicine sale

    The VAT treatment of pharmaceutical products depends on the supply and circumstances. Qualifying dispensing of prescribed medicines to individuals can be zero-rated, while wholesale supplies and many over-the-counter products are normally standard-rated. Certain healthcare services may be exempt, but a pharmaceutical business does not inherit a blanket healthcare exemption. Build product and transaction tax codes with supporting rules, including export evidence where relevant. Monitor the £90,000 taxable-turnover registration threshold: zero-rated sales count, even though their output VAT is nil. Overseas establishments and supply chains can create additional registration obligations.

    Assess R&D under the modern rules

    For accounting periods beginning on or after 1 April 2024, the merged R&D expenditure credit scheme and enhanced R&D intensive support replace the old schemes. The merged scheme offers a taxable 20% expenditure credit on eligible costs; this is not automatically a 20% cash refund. ERIS has separate conditions, including loss-making SME status and the R&D intensity requirement, generally 30%, subject to detailed rules. Assess scientific or technological uncertainty, cost eligibility, contracted-out work and overseas restrictions. Retain project narratives, competent-professional input and staff allocations, and check claim notification and additional-information requirements before filing.

    Separate financial runway from technical milestones

    A clinical milestone payment, grant receipt or investor subscription may have a different accounting treatment and timing from the associated research spend. Review contract obligations, repayment conditions and whether development expenditure meets the applicable recognition criteria; scientific optimism alone does not justify creating an intangible asset. Model trial overruns, batch failures and delayed receipts in a rolling cash forecast. Related-party licensing and cross-border royalties can require specialist transfer-pricing and withholding-tax analysis. Report committed purchase orders alongside ledger expenses so management sees expenditure already contracted but not yet invoiced.

    Hypothetical example: merged R&D credit is not the net benefit

    Assume a company has £200,000 of expenditure established as eligible under the merged scheme for a qualifying accounting period. A 20% gross expenditure credit is £40,000. If the entire credit is effectively taxed at 25% in this simplified illustration, the after-tax amount is £30,000: £40,000 less £10,000. Actual utilisation and payment follow statutory steps, including possible offsets, restrictions and the PAYE cap, so cash received may differ. Routine quality-control costs or overseas subcontractor invoices have not been assumed eligible simply because the company operates in pharmaceuticals. This is hypothetical, not a relief guarantee.

    How PRS Smart can help

    We agree the scope around your records, reporting needs and tax obligations, with clear responsibilities and an opportunity to discuss questions before work begins.

    Pharma questions

    Does every pharmaceutical company qualify for R&D relief?

    No. Eligibility is project- and expenditure-specific. Routine product changes, compliance activity or commercial novelty alone do not establish an advance in science or technology or qualifying uncertainty.

    Are all prescription medicine sales zero-rated?

    No. Qualifying dispensing to individuals must be distinguished from wholesale trade and other supplies. Use HMRC pharmaceutical guidance to classify the actual transaction rather than relying only on the product description.

    Can expired stock remain at original cost?

    Only where the applicable accounting valuation supports it, which expired or unsaleable products commonly will not. Document recoverable value, authorised disposal and any supplier recovery rather than leaving unsupported balances in inventory.

    Can PRS certify good distribution practice?

    No such claim is made. PRS can organise financial information and cost reporting, while MHRA licensing, regulatory inspections and specialist quality-system responsibilities remain with the relevant authorities and qualified professionals.

    Related reading

    UK guidance & sources

    Reviewed 20 November 2026. Examples are illustrative, not customer results; individual tax treatment depends on the facts and applicable rules.

    Discuss your pharma accounting needs

    +44 020 7011 8517 · clientcare@prssmart.com